잠시만 기다려 주세요. 로딩중입니다.

Safety Evaluation of Bilateral Same-day Intravitreal Ranibizumab Injections

검안 및 콘택트렌즈학회지 2020년 19권 3호 p.61 ~ 66
안자영, 장규환, 손준홍, 황덕진,
소속 상세정보
안자영 ( Ahn Ja-Young ) - HanGil Eye Hospital
장규환 ( Jang Kyu-Hwan ) - HanGil Eye Hospital
손준홍 ( Sohn Joon-Hong ) - HanGil Eye Hospital
황덕진 ( Hwang Duck-Jin ) - HanGil Eye Hospital

Abstract


Purpose: This study aimed to evaluate the safety of bilateral same-day intravitreal ranibizumab injections by analyzing ophthalmic complications.

Methods: Medical records of patients who underwent bilateral same-day intravitreal ranibizumab injections between January 2016 and December 2018 were retrospectively reviewed. Patient follow-up visits occurred 1 day, 1 month, and 2 months after the injections.

Results: The study included a total of 31 patients, 62 eyes, and 148 bilateral same-day intravitreal ranibizumab injections. The most frequent cause for treatment was exudative age-related macular degeneration, totaling 126 injections (85.1%). Diabetic macular edema accounted for 20 injections (13.5%), and macular edema due to retinal vein occlusion accounted for two injections (1.4%). There were no cases of endophthalmitis, retinal detachment, or vitreous hemorrhage in any patient. We observed five eyes (3.38%) with sterile inflammation, of which three improved without any treatment. The remaining two eyes were in a single patient, and the inflammation improved after four days of treatment. Four eyes (2.7%) exhibited vitreous floaters, and subconjunctival hemorrhage was observed in five eyes (3.38%).

Conclusions: The ocular complication rate of bilateral same-day intravitreal ranibizumab injection procedure was low.

키워드

Bilateral; Endophthalmitis; Intravitreal injection; Ranibizumab; Sterile inflammation

원문 및 링크아웃 정보

등재저널 정보